{"pmid":32212881,"title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","text":["Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","Immunotherapy","Bersanelli, Melissa","32212881"],"journal":"Immunotherapy","authors":["Bersanelli, Melissa"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32212881","week":"202013|Mar 23 - Mar 29","doi":"10.2217/imt-2020-0067","keywords":["anti-CTLA-4","COVID-19","SARS-CoV-2","anti-PD-1","anti-PD-L1","cancer patients","immune checkpoint inhibitors","immunotherapy","tocilizumab","viral infection"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1662445896472723457,"score":7.208847,"similar":[{"pmid":32218340,"title":"Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?","text":["Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?","The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 degrees C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available.","Int J Mol Sci","Jawhara, Samir","32218340"],"abstract":["The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 degrees C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available."],"journal":"Int J Mol Sci","authors":["Jawhara, Samir"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32218340","week":"202013|Mar 23 - Mar 29","doi":"10.3390/ijms21072272","keywords":["IVIg","coronavirus","immunotherapy","nCoV-2019","virus"],"source":"PubMed","locations":["China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662540582080217089,"score":70.631935},{"pmid":32219882,"title":"Controversial treatments: an updated understanding of the Coronavirus Disease 2019.","text":["Controversial treatments: an updated understanding of the Coronavirus Disease 2019.","An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system (ALS) and extracorporeal membrane oxygenation (ECMO), based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively. This article is protected by copyright. All rights reserved.","J Med Virol","Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong","32219882"],"abstract":["An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system (ALS) and extracorporeal membrane oxygenation (ECMO), based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219882","week":"202013|Mar 23 - Mar 29","doi":"10.1002/jmv.25788","keywords":["COVID-19","SARS-CoV-2","coronavirus","literature review","pneumonia","treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662540582101188608,"score":60.84501},{"pmid":32196933,"title":"Coronaviruses and immunosuppressed patients. The facts during the third epidemic.","text":["Coronaviruses and immunosuppressed patients. The facts during the third epidemic.","Following the outbreak in China, the Lombardy region of Italy has become one of the areas of highest incidence of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). As the outbreak grew to a pandemic, many centres worldwide raised the concern that immunocompromised patients may be at high risk of developing a severe respiratory disease called COVID-19. Unlike common viral agents (such as Adenovirus, Rhinovirus, Norovirus, Influenza, Respiratory Syncytial Virus), Coronaviruses have not shown to cause a more severe disease in immunosuppressed patients. For this family of viruses the host innate immune response appears the main driver of lung tissue damage during infection.","Liver Transpl","D'Antiga, Lorenzo","32196933"],"abstract":["Following the outbreak in China, the Lombardy region of Italy has become one of the areas of highest incidence of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). As the outbreak grew to a pandemic, many centres worldwide raised the concern that immunocompromised patients may be at high risk of developing a severe respiratory disease called COVID-19. Unlike common viral agents (such as Adenovirus, Rhinovirus, Norovirus, Influenza, Respiratory Syncytial Virus), Coronaviruses have not shown to cause a more severe disease in immunosuppressed patients. For this family of viruses the host innate immune response appears the main driver of lung tissue damage during infection."],"journal":"Liver Transpl","authors":["D'Antiga, Lorenzo"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196933","week":"202012|Mar 16 - Mar 22","doi":"10.1002/lt.25756","keywords":["Coronavirus","SARS","SARS-CoV-2,COVID-19","children","immunosuppression","liver","transplantation","viral infection"],"source":"PubMed","locations":["Norovirus","Lombardy","Rhinovirus","China","Italy","Coronaviruses"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Mechanism"],"weight":1,"_version_":1662334543133147136,"score":52.89341},{"pmid":32157732,"title":"Harnessing the immune system via FcgammaR function in immune therapy: A pathway to next-gen mAbs.","text":["Harnessing the immune system via FcgammaR function in immune therapy: A pathway to next-gen mAbs.","The human FcgammaRs interact with antigen-complexed IgG ligands to both activate and modulate a powerful network of inflammatory host-protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcgammaR-mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody-dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralise or remove small macromolecules such as cytokines or other immunoglobulins. The use of mAb therapeutics has also revealed a \"scaffolding\" role for FcgammaR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or may trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as SARS-CoV-2, requires increased effort on the development of improved and novel mAbs. A more mature appreciation of the immunobiology of individual FcgammaR function and the complexity of the relationships between FcgammaRs and antibodies is fuelling efforts to develop more potent \"next-gen\" therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for selective engagement of individual activating FcgammaRs or the inhibitory FcgammaRIIb or alternatively, for the ablation of FcgammaR interaction altogether. This review touches on recent aspects FcgammaR and IgG immunobiology and its relationship to the present and future actions of therapeutic mAbs.","Immunol Cell Biol","Chenoweth, Alicia M","Wines, Bruce D","Anania, Jessica C","Mark Hogarth, P","32157732"],"abstract":["The human FcgammaRs interact with antigen-complexed IgG ligands to both activate and modulate a powerful network of inflammatory host-protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcgammaR-mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody-dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralise or remove small macromolecules such as cytokines or other immunoglobulins. The use of mAb therapeutics has also revealed a \"scaffolding\" role for FcgammaR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or may trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as SARS-CoV-2, requires increased effort on the development of improved and novel mAbs. A more mature appreciation of the immunobiology of individual FcgammaR function and the complexity of the relationships between FcgammaRs and antibodies is fuelling efforts to develop more potent \"next-gen\" therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for selective engagement of individual activating FcgammaRs or the inhibitory FcgammaRIIb or alternatively, for the ablation of FcgammaR interaction altogether. This review touches on recent aspects FcgammaR and IgG immunobiology and its relationship to the present and future actions of therapeutic mAbs."],"journal":"Immunol Cell Biol","authors":["Chenoweth, Alicia M","Wines, Bruce D","Anania, Jessica C","Mark Hogarth, P"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32157732","week":"202011|Mar 09 - Mar 15","doi":"10.1111/imcb.12326","keywords":["ADCC","ADCP","Antibodies; Coronavirus","Fc Receptors","SARS-CoV-2","biologic drugs","immune agonism","monoclonal antibodies","phagocytosis","translational immunology"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543815770114,"score":48.74504},{"pmid":32061198,"title":"[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].","text":["[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].","The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality.","Zhonghua Jie He He Hu Xi Za Zhi","Sun, M L","Yang, J M","Sun, Y P","Su, G H","32061198"],"abstract":["The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Sun, M L","Yang, J M","Sun, Y P","Su, G H"],"date":"2020-02-16T11:00:00Z","year":2020,"_id":"32061198","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0014","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1662334544464838656,"score":47.09466}]}